


IFW

Application No.: 10/804,668

Docket No.: HO-P02680US1

Docket No.: HO-P02680US1
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
William A. Zoghbi et al.

Application No.: 10/804,668

Confirmation No.: 8004

Filed: March 19, 2004

Art Unit: N/A

For: USE OF BNP DURING STRESS TESTING
FOR THE DETECTION AND RISK
STRATIFICATION OF INDIVIDUALS
WITH SUSPECTED CORONARY ARTERY
DISEASE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached, except for the U.S. Patents which are not required to be provided.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02680US1. A duplicate copy of this paper is enclosed.

Dated: May 16, 2005

Respectfully submitted,

By 

Charles P. Landrum

Patent Agent

Registration No.: 46,855

FULBRIGHT & JAWORSKI L.L.P.

Fulbright Tower


1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Attorneys for Applicant



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/804,668
				Filing Date	March 19, 2004
				First Named Inventor	William A. Zoghbi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	HO-P02680US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-US 2003/0022235	01-30-2003	Dahlen et al.	
	AB	US-US 2003/0045908	03-06-2003	Condie et al.	
	AC	US-5,756,067	05-26-1998	Jones	
	AD	US-6,162,902	12/2000	Mischak et al.	
	AE	US-6,322,771	11-27-2001	Linden et al.	
	AF	US-6,376,207	04-23-2002	Nolan	
	AG	US-6,461,828	10-08-2002	Stanton, et al.	


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA	WO-WO 2002089657	05-04-2002	Biosite, Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Axis-Shield - News Article - BNP TESTS 9/17/02 OTA#02/093, "New Test Used to Spot Heart Failure"; Dallas Business Journal, v25n11, 2001-10-06	
	CB	BERGER, R. ET AL, "B-Type Natriuretic Peptides (BNP and Pro-BNP) Predict Longterm Survival in Patients with Advanced Heart Failure Treated with Atenolol"; J Heatt Lung Transplant. 20,251 (2001)	
	CC	BROCKHOFF C, ET AL; "Atrial natriuretic peptides: diagnostic and therapeutic poential" - Article in German - Abteilung fur Kardiologie, Universitatskrankenhaus Eppendorf, Hamburg, Germany; 4/8/2002	
	CD	CHO Y, ET AL.; "Natriuretic peptides and their therapeutic potential"; 4/8/2002; Department of Medicine, Brown University School of Medicine, Providence, Rhode Island, USA	
	CE	CLERICO A, ET AL.; "Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in a clinical practice: the need for a new generation of immunoassay methods"; Laboratory of Cardiovascular Endocrinology, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, University of Pisa, Pisa, Italy; 4/8/2002	
	CF	COWIE MR; "BNP: soon to become a routine measure in the care of patients with heart failure?"; 4/8/2002	
	CG	DE LEMOS, J.A., ET AL., "The Prognostic Value of B-Type Natriuretic Peptide in Patients with	

25535526		Date Considered	
.1			



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/804,668	
			Filing Date	March 19, 2004	
			First Named Inventor	William A. Zoghbi	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	HO-P02680US1

		Acute Coronary Syndromes"; N Engl J Med.. 345, 1014-21 (2001)	
	CH	DIAGNOSING HEART DISEASE (http://www.americanheart.org) September 17, 2002 - ABOUT RESEARCH; About VA R&D: News Releases About VA Research: Blood test for heart failure scores big in multinational trial	
	CI	DOOLITTLE, M.H. ET AL., "Immunodetection of Lipoprotein Lipase: Antibody Production, Immunoprecipitation, and Western Blotting Techniques"; Methods Mol Biol. 109, 215-371 (1999)	
	CJ	FISCHER, Y. ET AL., "Evaluation of a New, Rapid Bedside Test for Quantitative Determination of B-Type Natriuretic Peptide", Clin. Chem. 47, 591-594 (2001)	
	CK	JOURDAIN P, ET AL.; "Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol."; Service de Cardiologie Hopital R. Dubos, Pontoise, France; 11/21/2002	
	CL	KATO M, ET AL., "Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure."; 1st Department of Internal Medicine, Tottori University Faculty of Medicine, Yonago, Japan; 11/21/2002	
	CM	LATINI R, ET AL.; "What does the future hold for BNP in cardiology?"; 2/8/2002	
	CN	LEDER, ET AL.; "Myocardial ischemia and viability"; Clinic of Internal Medicine, Biomagnetic Centre, University of Jena, Jena, Germany (no date)	
	CO	MAIR J, ET AL.; "The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure"; Department of Internal Medicine, University of Innsbruck School of Medicine, Austria; 4/8/2002	
	CP	MARUMOTO K, ET AL., "Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris"; Clin Sci (Lond); 88: 551-556 (1995)	
	CQ	MCNAIRY M, ET AL.; "Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide."; ; Division of Cardiology and the Department of Medicine, Veteran's Affairs medical Center and University of California, San Diego, California; 11/21/2002	
	CR	NAGEH T, ET AL.; "Interpretation of plasma brain natriuretic peptide concentrations may require adjustment for patient's age."; 4/8/2002; Department of Cardiology, King's College Hospital, London, UK	
	CS	NAKAMURA M, ET AL.; "Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population"; 4/8/2002	
	CT	NICHOLSON S, ET AL.; "Atrial and brain natriuretic peptide response to exercise in pateints with ischaemic heart disease"; 11/21/2002	
	CU	NISHIKIMI T, ET AL.; "Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease."; Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, Japan; 4/19/2002	
	CV	OHBA H, ET AL.; "Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men"; Department of Cardiology, St. Mariana University School of Medicine, Kanagawa, Japan; 4/19/2002	
	CW	OMLAND, T., "Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term survival After Acute Myocardial Infarction", Circulation 1;93(11), 1963-9 (1996)	

25535526		Date Considered	
1			



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/804,668
				Filing Date	March 19, 2004
				First Named Inventor	William A. Zoghbi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	HO-P02680US1

	CX	PEACOCK WF 4TH; "The B-type natriuretic peptide assay: a rapid test for heart failure"; 4/8/2002	
	CY	STEIN, B., "Natriuretic peptides; Physiology, therapeutic potential, and risk stratification in ischemic heart disease"; C. Am Heart J. 135 (5Pt 1), 914-23 (1998)	
	CZ	VA Research Communications Service; "Quick Blood Test for Heart Failure Proves Successful in Multinational Trial"; Public Release Date 17 Jul 2002	
	CA1	VENUGOPAL J; "Cardiac natriuretic peptides--hope or hype?"; Department of Physiology and Pharmacology, Strathclyde Institute of Biomedical Sciences, University of Strathclyde, Glasgow, UK; 4/8/2002	
	CB1	WAKU S, ET AL.; "Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function"; Kansai University, Health Administration Center, Osaka, Japan; 4/8/2002	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

25535526 .1		Date Considered	
----------------	--	--------------------	--



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/804,668

Attorney Docket No.: HO-P02680US1

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on May 16, 2005
Date

Signature

Charles P. Landrum

Typed or printed name of person signing Certificate

46,855

Registration Number, if applicable

(713) 651-5391

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (3 pages) (with attachments)
Information Disclosure Statement (2 pages)